Department of Drug and Health Sciences, V.le A. Doria, 6, 95125 Catania, Italy
Office: +39 095/7384223
combine@combine-group.org

๐๐จ๐ฏ๐ž๐ฅ ๐ˆ๐ฆ๐ฆ๐ฎ๐ง๐จ๐ญ๐ก๐ž๐ซ๐š๐ฉ๐ข๐ž๐ฌ ๐Ÿ๐จ๐ซ ๐“๐ฎ๐›๐ž๐ซ๐œ๐ฎ๐ฅ๐จ๐ฌ๐ข๐ฌ ๐š๐ง๐ ๐จ๐ญ๐ก๐ž๐ซ ๐Œ๐ฒ๐œ๐จ๐›๐š๐œ๐ญ๐ž๐ซ๐ข๐š๐ฅ ๐ƒ๐ข๐ฌ๐ž๐š๐ฌ๐ž๐ฌ (๐ˆ๐“๐‡๐„๐Œ๐˜๐‚)

๐๐จ๐ฏ๐ž๐ฅ ๐ˆ๐ฆ๐ฆ๐ฎ๐ง๐จ๐ญ๐ก๐ž๐ซ๐š๐ฉ๐ข๐ž๐ฌ ๐Ÿ๐จ๐ซ ๐“๐ฎ๐›๐ž๐ซ๐œ๐ฎ๐ฅ๐จ๐ฌ๐ข๐ฌ ๐š๐ง๐ ๐จ๐ญ๐ก๐ž๐ซ ๐Œ๐ฒ๐œ๐จ๐›๐š๐œ๐ญ๐ž๐ซ๐ข๐š๐ฅ ๐ƒ๐ข๐ฌ๐ž๐š๐ฌ๐ž๐ฌ (๐ˆ๐“๐‡๐„๐Œ๐˜๐‚)

The Combine Group is delighted to announce our involvement in yet another project funded under the Horizon Europe Program:

Novel Immunotherapies for Tuberculosis and other Mycobacterial Diseases (ITHEMYC)

๐Ÿ’Š This venture is a significant opportunity to apply innovative solutions in silico modelling to facilitate both in vitro and in vivo preclinical progression and predict the therapeutic efficacy in the clinical stages of Tuberculosis.

๐Ÿคณ Stay updated on the latest developments of this cutting-edge project by following us on social media:

LinkedIn: https://lnkd.in/eua57aRt
Twitter: https://lnkd.in/eKDZp-vw

Leave a Reply

Your email address will not be published. Required fields are marked *